Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A double-blind clinical study that found ingestion of tocotrienols resulted in a 34.5% increase in hair regrowth compared to the placebo group, and discussion about potential side effects and cost of supplementation with vitamin E pills. The conversation noted that it may be more effective than commonly used treatments like minoxidil and finasteride.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.

The user is seeing positive results in hair growth using a combination of topical minoxidil, finasteride, microneedling, and keto shampoo. They also use a red light panel for collagen rebuilding and are happy with the progress.

The conversation is about someone's 3-month hair regrowth progress using 5mg oral minoxidil and 0.5mg dutasteride daily, with visible improvement noted.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

Hair loss treatment with finasteride, minoxidil, microneedling, and nizoral shows impressive results after 3 years. Dermatologist recommended starting with finasteride before adding other treatments.

The conversation is about a potential new hair loss treatment called Breezula CB-03-01. Users are discussing updates on its development and sharing personal experiences with making or using it.

The user is 3 months into using dutasteride and oral minoxidil after switching from finasteride, noticing potential regrowth with small hairs at the temples. They take 2.5mg oral minoxidil and 0.5mg dutasteride daily, with some eyelash and eyebrow growth observed.

PP405 shows promise for hair regrowth, with new hairs observed in 66% of patients in just 27 days. The discussion also mentions Minoxidil, finasteride, and RU58841 as potential treatments.

A 23-year-old experienced significant hair regrowth in 3 months using a topical mixture of minoxidil 5% and finasteride 1%, with added bimatoprost. The treatment is government-subsidized, costing around $15, and the user reported no side effects.

3aHSD enzyme's role in hair loss and a crowdfund for research. Goal: explore new treatments, study RU58841, and develop natural topical product.

PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.

A 25-year-old male shared his 3-month progress using oral minoxidil, finasteride, and biotin for hair growth, reporting positive results and minimal side effects, such as slightly reduced libido. He plans to continue treatment and possibly add microneedling, with hopes of further improvement and potential hair transplant if needed.

Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.

A 24-year-old shared three months of progress using dutasteride, minoxidil, and biotin for hair loss. The post includes progress pictures and discusses the effectiveness of these treatments.

ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.

Hair regrowth after 13 weeks using topical minoxidil, oral finasteride, peptide shampoo, serum, and a red light hat. Some growth is attributed to a recent hair transplant.

User restarted hair loss treatment with consistent finasteride, minoxidil, ketoconazole shampoo, and weekly dermarolling. Another user shared their regimen including dutasteride, oral minoxidil, RU58841, derma roller, ketoconazole shampoo, and stemoxydine.

A 52-year-old man experienced positive hair regrowth after three months on a daily regimen of 1mg finasteride and 3mg minoxidil. Users discussed dosage recommendations and shared advice on finasteride use, with some expressing amazement at the results.

The conversation discusses the potential of a new hair loss drug, CB-03-01, with users sharing their experiences and seeking advice on dosages and application methods. One user mentions using topical finasteride, minoxidil, dermarolling, and a clean diet for hair maintenance but is interested in CB-03-01 due to side effects from finasteride.

Follistatin, known for inhibiting myostatin and promoting muscle growth in mice, is being discussed as a potential treatment for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The conversation discusses hair loss linked to BDNF-increasing nootropics like Semax and Lions Mane. Suggested topical treatments include capsaicin, beta-glucan, and ginseng to counteract TGF-B activation.

A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.

The conversation is about when the phase 3 results for pyrilutamide, a potential hair loss treatment, will be released. There was a letter about the study a month ago, but the actual results were not included.

PP405 is a promising new treatment for hair loss. It performs three actions in one, potentially offering a cure.

Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.

The user experienced significant hair growth over three months using topical Minoxidil, microdosing Finasteride, microneedling, and ketoconazole shampoo. They also use Toppik hair fibers and Aveda hair thickening tonic for styling.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.